Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases：a Multicenter, Single-arm, Phase Ⅱ Trial

NCT07745257 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07745257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07745257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases：a Multicenter, Single-arm, Phase Ⅱ Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 28, 2026
Completion date
July 28, 2028
Enrollment
40 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hr-positive, her2-negative metastatic breast cancer with brain metastases